HelpHelp About Us Contact Contact Us Help Help
Press Release Service
user name password
Client login:   
First time user sign up Forgot your login info?
Website Directory     Submit Website

Search
EmailWire News Links

Home > News By Company > EIN News

Print e mail rss del Y! myWeb Tweet
 

FDA Approves AstraZeneca to Market Crestor to People without Cholesterol Problems







February 9, 2010 /EIN PRESSWIRE/ AstraZeneca has won FDA approval to market its cholesterol drug Crestor to people who have healthy cholesterol levels. Crestor can now be marketed to certain groups as a drug that can help reduce the risk of heart attack and stroke.

According to the AP, a 2008 study showed that Crestor reduced heart attacks, strokes and other problems by 44% in patients with normal cholesterol and slight heart disease risks. All patients had an elevated level of C-reactive protein, which is an indicator of inflammation that can lead to heart attack or stroke.

The FDA has now approved Crestor for men over 50 and women over 60 and who have elevated C-reactive protein levels and at least one risk factor for heart trouble, such as high blood pressure or a smoking habit.

Crestor is already AstraZeneca's third-best-selling drug, with revenue rising 29% to $4.5 billion last year, and now the FDA has cleared the way for up to 6 million more people in the US to buy the drug.

Read more about this story at Pharmaceutical Industry Today:

Latest Crestor news - http://pharmaceuticals.einnews.com/news/crestor
Latest AstraZeneca news - http://pharmaceuticals.einnews.com/news/astra-zeneca

Located at http://pharmaceuticals.einnews.com, Pharmaceutical Industry Today is a service of EIN News, an industry leader in news monitoring for business professionals and analysts. Using a combination of proprietary search technology and human editing, EIN News delivers to its members the latest pharmaceutical news from around the world, saving them valuable time they'd spend searching for information. New users to Pharmaceutical Industry Today can enjoy a no-obligation, one-week free trial.

About EIN Presswire
The EIN Presswire press release distribution service is a news-syndication solution that distributes news to more than 10 million visitors annually at EIN News and millions more through its press release distribution partners. A news source for leading journalists, decision-makers and industry professionals worldwide, EIN Presswire targets press releases to a wide array of worldwide business professionals in more than 80 different industries. EIN Presswire also offers affiliate network opportunities and news distribution to tens of thousands of news subscribers daily. Read the newest business news at http://www.einpresswire.com and the latest world news in more than 80 different industries at http://www.einnews.com.





This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International

Equityallianceir.com





Penny Stocks to Watch

Sign up for hot penny stock picks
Gains of 500%+ possible!

Premiumstockpicks.com/landing/




Your text Ads & 

PR

Text Ads plus unlimited press releases, One release featured/Day for only $575 per month.

Read more on Text Ads & PR






Your text Ads Here!

Text Ads are only $289 per month. Ads are placed same day.

More on Text Ads Advertising



 

Search


Advertising | How to contact us | Privacy Statement | EmailWire Press Releases | Partnership Opportunities

EmailWire is a press release distribution service of GroupWeb Media LLC.

© Copyright GroupWeb Media LLC 2012